Claim Editing Update Report: 4th Quarter 2017

Size: px
Start display at page:

Download "Claim Editing Update Report: 4th Quarter 2017"

Transcription

1 Claim Editing Update Report: 4th Quarter 2017 Page Section 1 McKesson Pair Additions pair edits added to the McKesson KnowledgePack Update. Site-specific modifier override indicators for denied/paid code combination. Y = does override; N = does not override; N/A = does not apply to the code combination. 24 McKesson Pair Rationale s Rationale descriptions for the rationale codes included in the McKesson Pair Additions section. 31 McKesson Pair Expirations pair edits closed from the McKesson KnowledgePack Update. 42 V23.3 Additions Edits added in new version of. Provides brief policy for each edit. 84 V23.3 Expirations Edits that were closed in new version of. 85 V23.2 Changes Changes to modifier overrides (new override = 1 or no longer overrides = 0) for existing code pairs and changes to existing edits' effective and/or expiration date. 89 OCE V23.3 Additions Edits added in new version of OCE/. 125 OCE V23.3 Expirations Edits that were closed in new version of OCE/. 126 OCE V23.3 Changes Changes to modifier overrides (new override = 1 or no longer overrides = 0) for existing code pairs and changes to existing edits' effective and/or expiration date. An independent licensee of the Blue Cross and Blue Shield Association

2 Instructions PLEASE REVIEW THE FOLLOWING IMPORTANT INFORMATION The information contained in this report is intended to expedite review of Horizon BCBSNJ rd quarter edit changes. Edits in the workbook are sorted first by denied code then by paid code in ascending numeric order. A '#' sign immediately Edit source abbreviations are defined below. Edits: code pair edits are code pairs that should not be reported together for a number of reasons explained in the National Correct Coding Initiative Coding Manual for Medicare Services. The Additions tab contains new edits added by (with policy statement). The Expirations tab contains edits expired by. The Deletions tab contains edits deleted by. The Changes tab contains edits modified by. Changes can include 1) ( "GB Indicator") modifications represented with a 'Modified' record and an 'Added' record, or 2) edit effective or expiration date modifications represented in one 'Modified' record. NOTE: An indicator of "1" = a modifier indicated by can be used to allow payment for both codes. "0" = No modifier can be used to bypass the edit pair. OCE/ Edits: edits incorporated into Outpatient Editor (OCE). The OCE/ Additions tab contains new edits added by OCE/ (with policy statement). The OCE/ Expirations tab contains edits expired by OCE/. The Deletions tab contains edits deleted by OCE/. The OCE/ Changes tab contains edits modified by OCE/. Changes can include 1) (OCE/ "GB Indicator") modifications represented with a 'Modified' record and an 'Added' record, or 2) edit effective or expiration date modifications represented in one 'Modified' record. NOTE: An indicator of "1" = a modifier indicated by OCE/ can be used to allow payment for both codes. "0" = No modifier can be used to bypass the edit pair. McKesson Pairs: This includes code pairs based on three of the rule types in the CXT UNBUN_PAIRS rule. These rule types are Incidental (INC), Mutually Exclusive (ME), and Parent/Child (ULT_PARENT) editing. An Edit Rationale number is provided with each McKesson Pair addition, which can be used to refer to the Edit Report Rationale worksheet where they are listed in numeric order. This Edit Rationale number is specific to this report only. General Information: s -25, -57, and -59 are intended to indicate that a service/procedure that would normally be included in payment for another service/procedure should, for specific reasons, not be denied when submitted with one of these modifiers. By default, modifier -25 will override any edit within the McKesson Pair Additions tab where the RULE_TYPE is ME or INC as well as any edit described in the McKesson Visits tab. By default, modifier -57 will override any edit described in the McKesson Visits tab. By default, modifier -59 will override any edit within the McKesson Pair Additions tab where the RULE_TYPE is ME, INC, or ULT_PARENT." Source Abbreviation Source Name Source Abbreviation Source Name AAOS American Academy of Orothopaedic Surgeons AUA American Urological Association. ACC American College of Cardiology. Correct Coding Initiative. ACOG American College of Obstetricians and Gynecologists. CCN External physician consultants. ACR American College of Radiology. CMS Centers for Medicare and Medicaid Services (CMS) coding guidelines. ACS American College of Surgeons DMEPOS DME Prosthetic, Orthotic, Supplies Fee Schedule AMA CPT coding guidelines. HPP Health Plan AMA RBRVS AMA RBRVS Data Manager PPP Internal physicians. ASA American Society of Anesthesiologists. SMFM Society for Maternal-Fetal Medicine. ASM American Society for Microbiology. STS Society of Thoracic Surgeons. ClaimsXten is a trademark of McKesson Corporation. CPT copyright 2017 American Medical Association. All rights reserved All other product and company names may be trademarks or registered trademarks of their respective companies.

3 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKIN COLOR 6.0 CM/< RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RESPIRATOR MOTION MGMT SIMUL /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< D RADIOTHERAPY PLAN /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION THERAPY DOSE PLAN /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIOTHERAPY DOSE PLAN IMRT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< TELETHX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< TELETHX ISODOSE PLAN CPLX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< BRACHYTX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< BRACHYTX ISODOSE INTERMED /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< BRACHYTX ISODOSE COMPLEX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SPECIAL TELETX PORT PLAN /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SPECIAL RADIATION DOSIMETRY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< DESIGN MLC DEVICE FOR IMRT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SRS MULTISOURCE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SRS LINEAR BASED /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SBRT DELIVERY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< NTSTY MODUL RAD TX DLVR SMPL /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< NTSTY MODUL RAD TX DLVR CPLX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< GUIDANCE FOR RADIAJ TX DLVR /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIOLOGY PORT IMAGES(S) /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< NEUTRON BEAM TX SIMPLE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< NEUTRON BEAM TX COMPLEX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< IO RAD TX DELIVERY BY X-RAY /1/2017 1

4 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKIN COLOR 6.0 CM/< IO RAD TX DELIVER BY ELCTRNS /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION TX MANAGEMENT X /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION THERAPY MANAGEMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< STEREOTACTIC RADIATION TRMT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SBRT MANAGEMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< IO RADIATION TX MANAGEMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< SPECIAL RADIATION TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< PROTON TRMT SIMPLE W/O COMP /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< PROTON TRMT SIMPLE W/COMP /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< PROTON TRMT INTERMEDIATE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< PROTON TREATMENT COMPLEX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< INFUSE RADIOACTIVE MATERIALS /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< APPLY INTRCAV RADIAT SIMPLE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< APPLY INTRCAV RADIAT INTERM /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< APPLY INTRCAV RADIAT COMPL /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< APPLY INTERSTIT RADIAT COMPL /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< APPLY SURF LDR RADIONUCLIDE /1/2017 INC CORRECT SKIN COLOR 6.0 CM/< RADIATION HANDLING /1/2017 INC CORRECT SKN COLOR CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKN COLOR CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKN COLOR CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKN COLOR CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKN COLOR CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKN COLOR CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKN COLOR CM RESPIRATOR MOTION MGMT SIMUL /1/2017 INC CORRECT SKN COLOR CM D RADIOTHERAPY PLAN /1/2017 INC CORRECT SKN COLOR CM RADIATION THERAPY DOSE PLAN /1/2017 2

5 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKN COLOR CM RADIOTHERAPY DOSE PLAN IMRT /1/2017 INC CORRECT SKN COLOR CM TELETHX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKN COLOR CM TELETHX ISODOSE PLAN CPLX /1/2017 INC CORRECT SKN COLOR CM BRACHYTX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKN COLOR CM BRACHYTX ISODOSE INTERMED /1/2017 INC CORRECT SKN COLOR CM BRACHYTX ISODOSE COMPLEX /1/2017 INC CORRECT SKN COLOR CM SPECIAL TELETX PORT PLAN /1/2017 INC CORRECT SKN COLOR CM SPECIAL RADIATION DOSIMETRY /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKN COLOR CM RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKN COLOR CM DESIGN MLC DEVICE FOR IMRT /1/2017 INC CORRECT SKN COLOR CM RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKN COLOR CM SRS MULTISOURCE /1/2017 INC CORRECT SKN COLOR CM SRS LINEAR BASED /1/2017 INC CORRECT SKN COLOR CM SBRT DELIVERY /1/2017 INC CORRECT SKN COLOR CM NTSTY MODUL RAD TX DLVR SMPL /1/2017 INC CORRECT SKN COLOR CM NTSTY MODUL RAD TX DLVR CPLX /1/2017 INC CORRECT SKN COLOR CM GUIDANCE FOR RADIAJ TX DLVR /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKN COLOR CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKN COLOR CM RADIOLOGY PORT IMAGES(S) /1/2017 INC CORRECT SKN COLOR CM NEUTRON BEAM TX SIMPLE /1/2017 INC CORRECT SKN COLOR CM NEUTRON BEAM TX COMPLEX /1/2017 INC CORRECT SKN COLOR CM IO RAD TX DELIVERY BY X-RAY /1/2017 INC CORRECT SKN COLOR CM IO RAD TX DELIVER BY ELCTRNS /1/2017 INC CORRECT SKN COLOR CM RADIATION TX MANAGEMENT X /1/2017 INC CORRECT SKN COLOR CM RADIATION THERAPY MANAGEMENT /1/2017 INC CORRECT SKN COLOR CM STEREOTACTIC RADIATION TRMT /1/2017 INC CORRECT SKN COLOR CM SBRT MANAGEMENT /1/2017 INC CORRECT SKN COLOR CM IO RADIATION TX MANAGEMENT /1/2017 INC CORRECT SKN COLOR CM SPECIAL RADIATION TREATMENT /1/2017 INC CORRECT SKN COLOR CM PROTON TRMT SIMPLE W/O COMP /1/2017 INC CORRECT SKN COLOR CM PROTON TRMT SIMPLE W/COMP /1/2017 3

6 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKN COLOR CM PROTON TRMT INTERMEDIATE /1/2017 INC CORRECT SKN COLOR CM PROTON TREATMENT COMPLEX /1/2017 INC CORRECT SKN COLOR CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKN COLOR CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKN COLOR CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKN COLOR CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKN COLOR CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKN COLOR CM INFUSE RADIOACTIVE MATERIALS /1/2017 INC CORRECT SKN COLOR CM APPLY INTRCAV RADIAT SIMPLE /1/2017 INC CORRECT SKN COLOR CM APPLY INTRCAV RADIAT INTERM /1/2017 INC CORRECT SKN COLOR CM APPLY INTRCAV RADIAT COMPL /1/2017 INC CORRECT SKN COLOR CM HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKN COLOR CM HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKN COLOR CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKN COLOR CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKN COLOR CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKN COLOR CM APPLY INTERSTIT RADIAT COMPL /1/2017 INC CORRECT SKN COLOR CM APPLY SURF LDR RADIONUCLIDE /1/2017 INC CORRECT SKN COLOR CM RADIATION HANDLING /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION THERAPY PLANNING /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SET RADIATION THERAPY FIELD /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RESPIRATOR MOTION MGMT SIMUL /1/2017 INC CORRECT SKIN COLOR EA 20.0CM D RADIOTHERAPY PLAN /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION THERAPY DOSE PLAN /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIOTHERAPY DOSE PLAN IMRT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM TELETHX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM TELETHX ISODOSE PLAN CPLX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM BRACHYTX ISODOSE PLAN SIMPLE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM BRACHYTX ISODOSE INTERMED /1/2017 INC CORRECT SKIN COLOR EA 20.0CM BRACHYTX ISODOSE COMPLEX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SPECIAL TELETX PORT PLAN /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SPECIAL RADIATION DOSIMETRY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT AID(S) /1/2017 4

7 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT AID(S) /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM DESIGN MLC DEVICE FOR IMRT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION PHYSICS CONSULT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SRS MULTISOURCE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SRS LINEAR BASED /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SBRT DELIVERY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM NTSTY MODUL RAD TX DLVR SMPL /1/2017 INC CORRECT SKIN COLOR EA 20.0CM NTSTY MODUL RAD TX DLVR CPLX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM GUIDANCE FOR RADIAJ TX DLVR /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TREATMENT DELIVERY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIOLOGY PORT IMAGES(S) /1/2017 INC CORRECT SKIN COLOR EA 20.0CM NEUTRON BEAM TX SIMPLE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM NEUTRON BEAM TX COMPLEX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM IO RAD TX DELIVERY BY X-RAY /1/2017 INC CORRECT SKIN COLOR EA 20.0CM IO RAD TX DELIVER BY ELCTRNS /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION TX MANAGEMENT X /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION THERAPY MANAGEMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM STEREOTACTIC RADIATION TRMT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SBRT MANAGEMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM IO RADIATION TX MANAGEMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM SPECIAL RADIATION TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM PROTON TRMT SIMPLE W/O COMP /1/2017 INC CORRECT SKIN COLOR EA 20.0CM PROTON TRMT SIMPLE W/COMP /1/2017 INC CORRECT SKIN COLOR EA 20.0CM PROTON TRMT INTERMEDIATE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM PROTON TREATMENT COMPLEX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HYPERTHERMIA TREATMENT /1/2017 INC CORRECT SKIN COLOR EA 20.0CM INFUSE RADIOACTIVE MATERIALS /1/2017 INC CORRECT SKIN COLOR EA 20.0CM APPLY INTRCAV RADIAT SIMPLE /1/2017 5

8 McKesson Pair Additions Rule Type Rationale Horizon Revised INC CORRECT SKIN COLOR EA 20.0CM APPLY INTRCAV RADIAT INTERM /1/2017 INC CORRECT SKIN COLOR EA 20.0CM APPLY INTRCAV RADIAT COMPL /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HDR RDNCL SKN SURF BRACHYTX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM HDR RDNCL NTRSTL/ICAV BRCHTX /1/2017 INC CORRECT SKIN COLOR EA 20.0CM APPLY INTERSTIT RADIAT COMPL /1/2017 INC CORRECT SKIN COLOR EA 20.0CM APPLY SURF LDR RADIONUCLIDE /1/2017 INC CORRECT SKIN COLOR EA 20.0CM RADIATION HANDLING /1/2017 INC NIPPLE EXPLORATION REMOVAL OF BREAST TISSUE /1/2017 INC NIPPLE EXPLORATION P-MASTECTOMY W/LN REMOVAL /1/2017 INC NIPPLE EXPLORATION MAST SIMPLE COMPLETE /1/2017 INC NIPPLE EXPLORATION MAST RADICAL /1/2017 INC NIPPLE EXPLORATION MAST RAD URBAN TYPE /1/2017 INC NIPPLE EXPLORATION MAST MOD RAD /1/2017 ME NECK SPINE FUSION CERVICAL LAMINOPLSTY 2/> SEG /1/2017 ME NECK SPINE FUSION C-LAMINOPLASTY W/GRAFT/PLATE /1/2017 ME SPINE FUSION EXTRA SEGMENT CERVICAL LAMINOPLSTY 2/> SEG /1/2017 ME SPINE FUSION EXTRA SEGMENT C-LAMINOPLASTY W/GRAFT/PLATE /1/2017 ME INSERT SPINE FIXATION DEVICE CERVICAL LAMINOPLSTY 2/> SEG /1/2017 ME INSERT SPINE FIXATION DEVICE C-LAMINOPLASTY W/GRAFT/PLATE /1/2017 ME INSERT SPINE FIXATION DEVICE CERVICAL LAMINOPLSTY 2/> SEG /1/2017 ME INSERT SPINE FIXATION DEVICE C-LAMINOPLASTY W/GRAFT/PLATE /1/2017 ME INSERT SPINE FIXATION DEVICE CERVICAL LAMINOPLSTY 2/> SEG /1/2017 ME INSERT SPINE FIXATION DEVICE C-LAMINOPLASTY W/GRAFT/PLATE /1/2017 INC REMOVE SHOULDER FB DEEP RECONSTRUCT SHOULDER JOINT /1/2017 INC REMOVE SHOULDER FB DEEP RECONSTRUCT SHOULDER JOINT /1/2017 INC SHOULDER PROSTHESIS REMOVAL RECONSTRUCT SHOULDER JOINT /1/2017 INC SHOULDER PROSTHESIS REMOVAL RECONSTRUCT SHOULDER JOINT /1/2017 INC SHOULDER PROSTHESIS REMOVAL RECONSTRUCT SHOULDER JOINT /1/2017 INC SHOULDER PROSTHESIS REMOVAL RECONSTRUCT SHOULDER JOINT /1/2017 INC REPAIR ELBOW PERC REVISE ULNAR NERVE AT ELBOW /1/2017 INC REPAIR ELBOW W/DEB OPEN REVISE ULNAR NERVE AT ELBOW /1/2017 INC REPAIR ELBOW DEB/ATTCH OPEN REVISE ULNAR NERVE AT ELBOW /1/2017 ME ABLATE INF TURBINATE SUPERF ABLATE INF TURBINATE SUBMUC /1/2017 INC COLONOSCOPY W/LESION REMOVAL COLONOSCOPY W/ABLATION /1/2017 6

9 McKesson Pair Additions Rule Type Rationale Horizon Revised INC COLONOSCOPY W/LESION REMOVAL COLONOSCOPY W/ABLATION /1/2017 ME EXTENSIVE VULVA SURGERY EXTENSIVE VULVA SURGERY /1/2017 ME CLOSURE OF VAGINA REPAIR OF VAGINA /1/2017 ME REPAIR PARAVAG DEFECT OPEN VAG HYST W/URINARY REPAIR /1/2017 ME REPAIR PARAVAG DEFECT VAG VAG HYST W/URINARY REPAIR /1/2017 ME REMOVE CERVIX REPAIR BOWEL COLPOPEXY INTRAPERITONEAL /1/2017 INC PIERCE SKULL IMPLANT DEVICE PIERCE SKULL FOR BIOPSY /1/2017 INC PIERCE SKULL IMPLANT DEVICE PIERCE SKULL FOR DRAINAGE /1/2017 INC PIERCE SKULL IMPLANT DEVICE PIERCE SKULL & REMOVE CLOT /1/2017 INC PIERCE SKULL IMPLANT DEVICE PIERCE SKULL FOR DRAINAGE /1/2017 INC INCISE SKULL FOR BRAIN WOUND INCISE SKULL FOR SURGERY /1/2017 ME SCAN PROC CRANIAL EXTRA SRS CRANIAL LESION SIMPLE /1/2017 ME SCAN PROC CRANIAL EXTRA SRS CRAN LES SIMPLE ADDL /1/2017 ME SCAN PROC CRANIAL EXTRA SRS CRANIAL LESION COMPLEX /1/2017 ME SCAN PROC CRANIAL EXTRA SRS CRAN LES COMPLEX ADDL /1/2017 ME SCAN PROC SPINAL SCAN PROC CRANIAL INTRA /1/2017 ME SCAN PROC SPINAL SRS CRANIAL LESION SIMPLE /1/2017 ME SCAN PROC SPINAL SRS CRAN LES SIMPLE ADDL /1/2017 ME SCAN PROC SPINAL SRS CRANIAL LESION COMPLEX /1/2017 ME SCAN PROC SPINAL SRS CRAN LES COMPLEX ADDL /1/2017 ME REMOVE SPINAL LAMINA ADD-ON DECOMPRESS SPINAL CORD LMBR /1/2017 ME DECOMPRESS SPINE CORD ADD-ON REMOVE SPINE LAMINA 1 LMBR /1/2017 INC REVISE LOW BACK NERVE(S) REMOVE SPINE LAMINA 1 THRC /1/2018 INC REVISE LOW BACK NERVE(S) REMOVE SPINE LAMINA 1 LMBR /1/2018 INC REVISE LOW BACK NERVE(S) DECOMPRESS SPINAL CORD THRC /1/2018 INC REVISE LOW BACK NERVE(S) DECOMPRESS SPINAL CORD LMBR /1/2018 INC REVISE LOW BACK NERVE(S) DECOMPRESS SPINE CORD ADD-ON /1/2018 ME CT ANGIOGRAPH PELV W/O&W/DYE CT ANGIO LWR EXTR W/O&W/DYE /1/2017 INC US GUIDE TISSUE ABLATION 0440T ABLTJ PERC UXTR/PERPH NRV /1/2017 INC US GUIDE TISSUE ABLATION 0441T ABLTJ PERC LXTR/PERPH NRV /1/2017 INC US GUIDE TISSUE ABLATION 0442T ABLTJ PERC PLEX/TRNCL NRV /1/2017 INC CT GUIDE FOR TISSUE ABLATION 0440T ABLTJ PERC UXTR/PERPH NRV /1/2017 INC CT GUIDE FOR TISSUE ABLATION 0441T ABLTJ PERC LXTR/PERPH NRV /1/2017 INC CT GUIDE FOR TISSUE ABLATION 0442T ABLTJ PERC PLEX/TRNCL NRV /1/2017 INC MRI FOR TISSUE ABLATION 0440T ABLTJ PERC UXTR/PERPH NRV /1/2017 INC MRI FOR TISSUE ABLATION 0441T ABLTJ PERC LXTR/PERPH NRV /1/2017 INC MRI FOR TISSUE ABLATION 0442T ABLTJ PERC PLEX/TRNCL NRV /1/2017 7

10 McKesson Pair Additions Rule Type Rationale Horizon Revised ME RADIUM/RADIOISOTOPE THERAPY THORAX STEREO RAD TARGETW/TX /1/2017 ME DRUG SCREEN QUANTALCOHOLS G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREEN QUANTALCOHOLS G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREEN QUANTALCOHOLS G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREEN QUANTALCOHOLS G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREEN QUANTALCOHOLS G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ALCOHOLS BIOMARKERS 1OR 2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 1OR 2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 1OR 2 G0482 DRUG TEST DEF CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 1OR 2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 1OR 2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ALCOHOLS BIOMARKERS 3/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 3/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 3/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 3/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ALCOHOLS BIOMARKERS 3/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREEN AMPHETAMINES 1/2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREEN AMPHETAMINES 1/2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREEN AMPHETAMINES 1/2 G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREEN AMPHETAMINES 1/2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREEN AMPHETAMINES 1/2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME AMPHETAMINES 3OR 4 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME AMPHETAMINES 3OR 4 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME AMPHETAMINES 3OR 4 G0482 DRUG TEST DEF CLASSES /1/2017 ME AMPHETAMINES 3OR 4 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME AMPHETAMINES 3OR 4 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME AMPHETAMINES 5 OR MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME AMPHETAMINES 5 OR MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME AMPHETAMINES 5 OR MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME AMPHETAMINES 5 OR MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME AMPHETAMINES 5 OR MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANABOLIC STEROID 1 OR 2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANABOLIC STEROID 1 OR 2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANABOLIC STEROID 1 OR 2 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANABOLIC STEROID 1 OR 2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANABOLIC STEROID 1 OR 2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANABOLIC STEROID 3 OR MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 8

11 McKesson Pair Additions Rule Type Rationale Horizon Revised ME ANABOLIC STEROID 3 OR MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANABOLIC STEROID 3 OR MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME ANABOLIC STEROID 3 OR MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANABOLIC STEROID 3 OR MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANALGESICS NON-OPIOID 1 OR 2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 1 OR 2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 1 OR 2 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANALGESICS NON-OPIOID 1 OR 2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANALGESICS NON-OPIOID 1 OR 2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANALGESICS NON-OPIOID 3-5 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 3-5 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 3-5 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANALGESICS NON-OPIOID 3-5 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANALGESICS NON-OPIOID 3-5 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANALGESICS NON-OPIOID 6/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 6/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANALGESICS NON-OPIOID 6/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME ANALGESICS NON-OPIOID 6/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANALGESICS NON-OPIOID 6/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANTIDEPRESSANTS CLASS 1 OR 2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 1 OR 2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 1 OR 2 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 1 OR 2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 1 OR 2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANTIDEPRESSANTS CLASS 3-5 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 3-5 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 3-5 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 3-5 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 3-5 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANTIDEPRESSANTS CLASS 6/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 6/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 6/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 6/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANTIDEPRESSANTS CLASS 6/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANTIDEPRESSANT TRICYCLIC 1/2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 1/2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 1/2 G0482 DRUG TEST DEF CLASSES /1/2017 9

12 McKesson Pair Additions Rule Type Rationale Horizon Revised ME ANTIDEPRESSANT TRICYCLIC 1/2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 1/2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME ANTIDEPRESSANT TRICYCLIC 3-5 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 3-5 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 3-5 G0482 DRUG TEST DEF CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 3-5 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME ANTIDEPRESSANT TRICYCLIC 3-5 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME TRICYCLIC & CYCLICALS 6/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME TRICYCLIC & CYCLICALS 6/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME TRICYCLIC & CYCLICALS 6/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME TRICYCLIC & CYCLICALS 6/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME TRICYCLIC & CYCLICALS 6/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING BARBITURATES ASSAY OF PHENOBARBITAL /1/2017 ME DRUG SCREENING BARBITURATES G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING BARBITURATES G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING BARBITURATES G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING BARBITURATES G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING BARBITURATES G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME BENZODIAZEPINES1-12 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME BENZODIAZEPINES1-12 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME BENZODIAZEPINES1-12 G0482 DRUG TEST DEF CLASSES /1/2017 ME BENZODIAZEPINES1-12 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME BENZODIAZEPINES1-12 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME BENZODIAZEPINES 13 OR MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME BENZODIAZEPINES 13 OR MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME BENZODIAZEPINES 13 OR MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME BENZODIAZEPINES 13 OR MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME BENZODIAZEPINES 13 OR MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING BUPRENORPHINE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING BUPRENORPHINE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING BUPRENORPHINE G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING BUPRENORPHINE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING BUPRENORPHINE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME CANNABINOIDS NATURAL G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME CANNABINOIDS NATURAL G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME CANNABINOIDS NATURAL G0482 DRUG TEST DEF CLASSES /1/2017 ME CANNABINOIDS NATURAL G0483 DRUG TEST DEF 22+ CLASSES /1/

13 McKesson Pair Additions Rule Type Rationale Horizon Revised ME CANNABINOIDS NATURAL G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME CANNABINOIDS SYNTHETIC 1-3 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 1-3 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 1-3 G0482 DRUG TEST DEF CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 1-3 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 1-3 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME CANNABINOIDS SYNTHETIC 4-6 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 4-6 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 4-6 G0482 DRUG TEST DEF CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 4-6 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME CANNABINOIDS SYNTHETIC 4-6 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME CANNABINOID SYNTHETIC 7/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME CANNABINOID SYNTHETIC 7/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME CANNABINOID SYNTHETIC 7/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME CANNABINOID SYNTHETIC 7/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME CANNABINOID SYNTHETIC 7/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING COCAINE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING COCAINE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING COCAINE G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING COCAINE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING COCAINE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING FENTANYL G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING FENTANYL G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING FENTANYL G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING FENTANYL G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING FENTANYL G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME GABAPENTIN NON-BLOOD DRUG SCREEN QUANT GABAPENTIN /1/2017 ME GABAPENTIN NON-BLOOD G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME GABAPENTIN NON-BLOOD G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME GABAPENTIN NON-BLOOD G0482 DRUG TEST DEF CLASSES /1/2017 ME GABAPENTIN NON-BLOOD G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME GABAPENTIN NON-BLOOD G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME HEROIN METABOLITE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME HEROIN METABOLITE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME HEROIN METABOLITE G0482 DRUG TEST DEF CLASSES /1/2017 ME HEROIN METABOLITE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME HEROIN METABOLITE G0659 DRUG TEST DEF SIMPLE ALL CL /1/

14 McKesson Pair Additions Rule Type Rationale Horizon Revised ME KETAMINE AND NORKETAMINE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME KETAMINE AND NORKETAMINE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME KETAMINE AND NORKETAMINE G0482 DRUG TEST DEF CLASSES /1/2017 ME KETAMINE AND NORKETAMINE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME KETAMINE AND NORKETAMINE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING METHADONE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING METHADONE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING METHADONE G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING METHADONE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING METHADONE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME METHYLENEDIOXYAMPHETAMINES G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME METHYLENEDIOXYAMPHETAMINES G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME METHYLENEDIOXYAMPHETAMINES G0482 DRUG TEST DEF CLASSES /1/2017 ME METHYLENEDIOXYAMPHETAMINES G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME METHYLENEDIOXYAMPHETAMINES G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME METHYLPHENIDATE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME METHYLPHENIDATE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME METHYLPHENIDATE G0482 DRUG TEST DEF CLASSES /1/2017 ME METHYLPHENIDATE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME METHYLPHENIDATE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME OPIATES 1 OR MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME OPIATES 1 OR MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME OPIATES 1 OR MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME OPIATES 1 OR MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME OPIATES 1 OR MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME OPIOIDS & OPIATE ANALOGS 1/2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 1/2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 1/2 G0482 DRUG TEST DEF CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 1/2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 1/2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME OPIOIDS & OPIATE ANALOGS 3/4 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 3/4 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 3/4 G0482 DRUG TEST DEF CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 3/4 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME OPIOIDS & OPIATE ANALOGS 3/4 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME OPIOID &OPIATE ANALOG 5/MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME OPIOID &OPIATE ANALOG 5/MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/

15 McKesson Pair Additions Rule Type Rationale Horizon Revised ME OPIOID &OPIATE ANALOG 5/MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME OPIOID &OPIATE ANALOG 5/MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME OPIOID &OPIATE ANALOG 5/MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING OXYCODONE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING OXYCODONE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING OXYCODONE G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING OXYCODONE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING OXYCODONE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING PREGABALIN G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING PREGABALIN G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING PREGABALIN G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING PREGABALIN G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING PREGABALIN G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING PROPOXYPHENE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING PROPOXYPHENE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING PROPOXYPHENE G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING PROPOXYPHENE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING PROPOXYPHENE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME SEDATIVE HYPNOTICS G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME SEDATIVE HYPNOTICS G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME SEDATIVE HYPNOTICS G0482 DRUG TEST DEF CLASSES /1/2017 ME SEDATIVE HYPNOTICS G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME SEDATIVE HYPNOTICS G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME SKELETAL MUSCLE RELAXANT 1/2 G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME SKELETAL MUSCLE RELAXANT 1/2 G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME SKELETAL MUSCLE RELAXANT 1/2 G0482 DRUG TEST DEF CLASSES /1/2017 ME SKELETAL MUSCLE RELAXANT 1/2 G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME SKELETAL MUSCLE RELAXANT 1/2 G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME SKEL MUSC RELAXANT 3 OR MORE G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME SKEL MUSC RELAXANT 3 OR MORE G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME SKEL MUSC RELAXANT 3 OR MORE G0482 DRUG TEST DEF CLASSES /1/2017 ME SKEL MUSC RELAXANT 3 OR MORE G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME SKEL MUSC RELAXANT 3 OR MORE G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME STIMULANTS SYNTHETIC G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME STIMULANTS SYNTHETIC G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME STIMULANTS SYNTHETIC G0482 DRUG TEST DEF CLASSES /1/2017 ME STIMULANTS SYNTHETIC G0483 DRUG TEST DEF 22+ CLASSES /1/

16 McKesson Pair Additions Rule Type Rationale Horizon Revised ME STIMULANTS SYNTHETIC G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING TAPENTADOL G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING TAPENTADOL G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING TAPENTADOL G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING TAPENTADOL G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING TAPENTADOL G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME DRUG SCREENING TRAMADOL G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME DRUG SCREENING TRAMADOL G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME DRUG SCREENING TRAMADOL G0482 DRUG TEST DEF CLASSES /1/2017 ME DRUG SCREENING TRAMADOL G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME DRUG SCREENING TRAMADOL G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 ME STEREOISOMER ANALYSIS G0480 DRUG TEST DEF 1-7 CLASSES /1/2017 ME STEREOISOMER ANALYSIS G0481 DRUG TEST DEF 8-14 CLASSES /1/2017 ME STEREOISOMER ANALYSIS G0482 DRUG TEST DEF CLASSES /1/2017 ME STEREOISOMER ANALYSIS G0483 DRUG TEST DEF 22+ CLASSES /1/2017 ME STEREOISOMER ANALYSIS G0659 DRUG TEST DEF SIMPLE ALL CL /1/2017 INC URINALYSIS AUTO W/O SCOPE DRUG SCREEN QUANTALCOHOLS /1/2017 INC URINALYSIS AUTO W/O SCOPE ALCOHOLS BIOMARKERS 1OR /1/2017 INC URINALYSIS AUTO W/O SCOPE ALCOHOLS BIOMARKERS 3/MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE DRUG SCREEN AMPHETAMINES 1/ /1/2017 INC URINALYSIS AUTO W/O SCOPE AMPHETAMINES 3OR /1/2017 INC URINALYSIS AUTO W/O SCOPE AMPHETAMINES 5 OR MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE ANABOLIC STEROID 1 OR /1/2017 INC URINALYSIS AUTO W/O SCOPE ANABOLIC STEROID 3 OR MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE ANALGESICS NON-OPIOID 1 OR /1/2017 INC URINALYSIS AUTO W/O SCOPE ANALGESICS NON-OPIOID /1/2017 INC URINALYSIS AUTO W/O SCOPE ANALGESICS NON-OPIOID 6/MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE ANTIDEPRESSANTS CLASS 1 OR /1/2017 INC URINALYSIS AUTO W/O SCOPE ANTIDEPRESSANTS CLASS /1/2017 INC URINALYSIS AUTO W/O SCOPE ANTIDEPRESSANTS CLASS 6/MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE ANTIDEPRESSANT TRICYCLIC 1/ /1/2017 INC URINALYSIS AUTO W/O SCOPE ANTIDEPRESSANT TRICYCLIC /1/2017 INC URINALYSIS AUTO W/O SCOPE TRICYCLIC & CYCLICALS 6/MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE DRUG SCREENING BARBITURATES /1/2017 INC URINALYSIS AUTO W/O SCOPE BENZODIAZEPINES /1/2017 INC URINALYSIS AUTO W/O SCOPE BENZODIAZEPINES 13 OR MORE /1/2017 INC URINALYSIS AUTO W/O SCOPE DRUG SCREENING BUPRENORPHINE /1/

CODING GUIDELINES. Radiation Therapy. Effective January 1, 2018

CODING GUIDELINES. Radiation Therapy. Effective January 1, 2018 CODING GUIDELINES Radiation Therapy Effective January 1, 2018 Coding guidelines for medical necessity review of radiation therapy services. 2018 evicore healthcare. All rights reserved. Please note the

More information

MRI-Guided On-line Adaptive Radiotherapy The UCLA Physics Experience. Disclosures 8/3/2016

MRI-Guided On-line Adaptive Radiotherapy The UCLA Physics Experience. Disclosures 8/3/2016 MRI-Guided On-line Adaptive Radiotherapy The UCLA Physics Experience James Lamb, Nzhde Agazaryan, Minsong Cao, Mitch Kamrava, Percy Lee, Daniel Low, David Thomas, Yingli Yang Department of Radiation Oncology

More information

Quick Reference Instructions

Quick Reference Instructions PROFILE -V Quick Reference Instructions Reader System Before performing the test, refer to the PROFILE -V MEDTOXScan Drugs of Abuse Test System Insert and MEDTOXScan User Manual for complete operating

More information

CITY OF MOBILE. Purchasing Department and Package Delivery: Government Plaza 4th Floor, Room S Government St Mobile, Alabama 36644

CITY OF MOBILE. Purchasing Department and Package Delivery: Government Plaza 4th Floor, Room S Government St Mobile, Alabama 36644 Typed by: DATE Mailing Address: P. 0. Box 1948 Mobile, Alabama 36633 (251) 208-7434 nm Buyer: CITY OF MOBILE Purchasing Department and Package Delivery: Government Plaza 4th Floor, Room S-408 205 Government

More information

Reimbursement & Coding for Radiation Oncology

Reimbursement & Coding for Radiation Oncology Reimbursement & Coding for Radiation Oncology HSCO November 2015 Contact Information Revenue Cycle Inc. 1817 W. Braker Lane Bldg. F, Suite 200 Austin, Texas 78758 www.revenuecycleinc.com (512) 583-2000

More information

BlueOptions Prime Plus Plan

BlueOptions Prime Plus Plan BlueOptions Prime Plus Plan Schedule of Benefits Plan 03766 Important things to keep in mind as you review this Schedule of Benefits: This Schedule of Benefits is part of your Benefit Booklet, where more

More information

Coding Systems Understanding NDC and HCPCS

Coding Systems Understanding NDC and HCPCS Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier for prescription medications approved for human consumption. According

More information

Chargemaster Fundamentals for a Solid Revenue Cycle Foundation. November 7, 2012 John Behn

Chargemaster Fundamentals for a Solid Revenue Cycle Foundation. November 7, 2012 John Behn Chargemaster Fundamentals for a Solid Revenue Cycle Foundation Understanding the Importance, Purpose and Function of your Charge Data Master November 7, 2012 John Behn National Rural Health Resource Center

More information

Medicare Hospital Outpatient Prospective Payment System

Medicare Hospital Outpatient Prospective Payment System Medicare Hospital Outpatient Prospective Payment System PROPOSED RULE FOR CALENDAR YEAR 2018 August 9, 2017 OPPS Proposed Rule for CY 2018 QUICK FACTS WHO? Centers for Medicare and Medicaid (CMS) WHAT?

More information

North Carolina Medicaid Special Bulletin

North Carolina Medicaid Special Bulletin North Carolina Medicaid Special Bulletin An Information Service of the Division of Medical Assistance Visit DMA on the Web at http://www.ncdhhs.gov/dma December 2014 Attention: All Providers Modifier 59

More information

E2E SBRT Thorax Phantom

E2E SBRT Thorax Phantom E2E SBRT Thorax Phantom Model 036A-CVXX-xx SBRT END-TO-END SBRT TESTING SOLUTION SCAN PLAN LOCALIZE TREAT This product is available through: JRT Associates 800-22-0 2428 Almeda Avenue Suite 36 Norfolk,

More information

Understanding The Provider Registration Scorecard. Powered By

Understanding The Provider Registration Scorecard. Powered By Understanding The Provider Registration Scorecard Powered By Understanding Your Scorecard The provider registration scorecard is divided into section scores based on the information that your facility

More information

Eliminating Infusion Confusion

Eliminating Infusion Confusion Eliminating Infusion Confusion (Drug Administrations in Non-facility Settings) Maryann C. Palmeter, CPC, CENTC Agenda Review of CPT codes (added in 2009) Documentation principles Key definitions What s

More information

CORPORATE POLICY SUBSTANCE ABUSE POLICY SCOPE

CORPORATE POLICY SUBSTANCE ABUSE POLICY SCOPE ORIGINAL EFFECTIVE: REVISION NO. REVISION EFFECTIVE: CORPORATE POLICY POLICY NO. PAGE NO. 1 SUBSTANCE ABUSE POLICY SCOPE This policy applies to all* regular status full-time and part-time employees of

More information

RapidArc: Clinical Implementation

RapidArc: Clinical Implementation RapidArc: Clinical Implementation Fang-Fang Yin, PhD Q. Jackie Wu, PhD Acknowledgements Team efforts from staff at Duke Radiation Oncology, especially to Dr. J Chang, Dr. J O Daniel for providing slide

More information

Strategies for Adaptive RT

Strategies for Adaptive RT Strategies for Adaptive RT Olga L. Green Disclosures Honoraria and travel grants from ViewRay, Inc. 1 Learning Objectives What is ART? What is needed to implement real-time, online ART in the clinic? Example

More information

EvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process.

EvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process. Classification of Approvals from Devices@FDA FDA Classification EvaluateMedTech has used a number of sources within the Devices@FDA site to develop a 4-level classification tree based on the FDA approvals

More information

MEDICAL PHYSICS (MED PHYS)

MEDICAL PHYSICS (MED PHYS) Medical Physics (MED PHYS) 1 MEDICAL PHYSICS (MED PHYS) MED PHYS/PHYSICS 265 INTRODUCTION TO MEDICAL PHYSICS Primarily for premeds and other students in the medical and biological sciences. Applications

More information

Diagnosis for Open Wounds as a Result of Cancer Resection

Diagnosis for Open Wounds as a Result of Cancer Resection Diagnosis for Open Wounds as a Result of Cancer Resection December 15, 2016 What diagnosis code do we use when we are reconstructing a defect after the Moh s surgeon, or someone else removed the cancer?

More information

ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES

ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES Overview This document provides all new, revised and existing Policies and all new, revised and existing claims editing rules administered

More information

Physician Office Billing & Payment Guide

Physician Office Billing & Payment Guide Physician Office Billing & Payment Guide Dermal Regeneration Matrix Dermal Repair Scaffold Ag Antimicrobial Dermal Repair Scaffold Physician Office Billing & Payment Guide Billing and Medicare Payment

More information

Calendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule

Calendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule Calendar Year 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule August 2017 This document is presented for informational purposes only and is not intended to provide reimbursement

More information

WHAT THE DATA HAS TO SHOW: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry

WHAT THE DATA HAS TO SHOW: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry 14 th Annual Spine, Orthopedic and Pain Management-Driven ASC Conference + The Future of Spine WHAT THE DATA HAS TO SHOW: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic

More information

InterQual View Quick Reference. Change Healthcare Operations LLC Product Support

InterQual View Quick Reference. Change Healthcare Operations LLC  Product Support InterQual View 2017 Quick Reference Change Healthcare Operations LLC www.changehealthcare.com Product Support 800.274.8374 General Terms: Change Healthcare Operations, LLC and/or one of its subsidiaries

More information

Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons

Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons Ottawa, Ontario, Canada 1 March 2012 Richard Johnson, Ph.D.

More information

Treatment Quality Assurance Cone Beam Image Guided Radiation Therapy. Jean-Pierre Bissonnette, PhD, MCCPM

Treatment Quality Assurance Cone Beam Image Guided Radiation Therapy. Jean-Pierre Bissonnette, PhD, MCCPM Treatment Quality Assurance Cone Beam Image Guided Radiation Therapy Jean-Pierre Bissonnette, PhD, MCCPM Disclosure Work supported, in part, by Elekta Oncology Systems Commercial Interest in Penta-Guide

More information

Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety

Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety Quality ID #262: Image Confirmation of Successful Excision of Image-Localized Breast Lesion National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Line # Item Number Item/Description Category Co Item UOM Contract Price

Line # Item Number Item/Description Category Co Item UOM Contract Price Main 248/858-0511 1 of 6 1 000000000000022073 Ten Panel Dip screw cap collection bottles and temperature strips AMP/BAR/BZO/COC/MAMP/MTD/OPI(300)/PCP/TCA/THC - P/N 011020025, (25 /box) 42140000 EA 3.25

More information

Stem cells and motor neurone disease

Stem cells and motor neurone disease Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current

More information

InterQual View Quick Reference. Change Healthcare LLC Product Support

InterQual View Quick Reference. Change Healthcare LLC  Product Support InterQual View 2018 Quick Reference Change Healthcare LLC www.changehealthcare.com Product Support 800.274.8374 PROPRIETARY NOTICE General Terms: Change Healthcare LLC and/or one of its subsidiaries (

More information

How GE Research Developed MRI (Magnetic Resonance Imaging) Guided Surgery By Kirby Vosburgh

How GE Research Developed MRI (Magnetic Resonance Imaging) Guided Surgery By Kirby Vosburgh How GE Research Developed MRI (Magnetic Resonance Imaging) Guided Surgery By Kirby Vosburgh GE Corporate Research and Development (CRD) and GE Medical Systems (GEMS) have collaborated since the 1970s on

More information

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular

More information

Guidance for the Physics Aspects of Clinical Trials

Guidance for the Physics Aspects of Clinical Trials AAPM REPORT NO. 113 Guidance for the Physics Aspects of Clinical Trials The Report of AAPM Task Group 113 January 2018 DISCLAIMER: This publication is based on sources and information believed to be reliable,

More information

Introducing a new take on efficient workflow: Deeply integrated clinical applications

Introducing a new take on efficient workflow: Deeply integrated clinical applications Clinical Applications Introducing a new take on efficient workflow: Deeply integrated clinical applications The EXPERIENCE of TRUE CLINICAL APPLICATIONS While developments in image acquisition technology

More information

Coding Essentials for Infusion and Injection Therapy Services 2018

Coding Essentials for Infusion and Injection Therapy Services 2018 Coding Essentials for Infusion and Injection Therapy Services 2018 A guide for outpatient injections, non-chemotherapy and chemotherapy administration services Prepared and Published By: MedLearn Publishing

More information

Varian MCO Benefits in Head and Neck Planning

Varian MCO Benefits in Head and Neck Planning Varian MCO Benefits in Head and Neck Planning Dominic DiCostanzo, MS, DABR November 3, 2017 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research

More information

Stem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean?

Stem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean? STO-120 Stem Cells Part 1: What is a Stem Cell? Stem cells differ from other kinds of cells in the body. When a stem cell divides by mitosis, each new cell has the potential to either remain a stem cell

More information

HITT 1211 Final Exam Review (Chap 1-12)

HITT 1211 Final Exam Review (Chap 1-12) HITT 1211 Final Exam Review (Chap 1-12) This exam is a two-part exam consisting of a comprehensive, closed-book exam over lecture text chapters 1 12 and a closed-book skills exam demonstrating your skills

More information

Treatment planning for scanned proton beams and IMPT

Treatment planning for scanned proton beams and IMPT Treatment planning for scanned proton SFUD IMPT Tony Lomax, Centre for Proton Radiotherapy, Paul Scherrer Institute, Switzerland Treatment planning for scanning 1. Principles of treatment planning for

More information

Lytec Features Evolution Matrix

Lytec Features Evolution Matrix Insurance Apply Payment Wizard Authorization/Referral Tracking Auto Fee Schedule Update Multi-location Fee Schedule Management Batch Eligibility Verification Capture Scanned Images of Insurance Cards Compress

More information

We help you care! new art laboratories. High quality in-vitro diagnostic products. Rapid Tests. Laboratory Diagnostics. Laboratory Service

We help you care! new art laboratories. High quality in-vitro diagnostic products. Rapid Tests. Laboratory Diagnostics. Laboratory Service new art laboratories We help you care! High quality in-vitro diagnostic products Rapid Tests Laboratory Diagnostics Laboratory Service Consulting & Service nal von minden A story of success For 30 years

More information

Target point correction optimized based on the dose distribution of each fraction in daily IGRT

Target point correction optimized based on the dose distribution of each fraction in daily IGRT Journal of Physics: Conference Series OPEN ACCESS Target point correction optimized based on the dose distribution of each fraction in daily IGRT To cite this article: Markus Stoll et al 2014 J. Phys.:

More information

Adaptive Re-planning for Lung RT with Multi-targets

Adaptive Re-planning for Lung RT with Multi-targets Adaptive Re-planning for Lung RT with Multi-targets Feng Liu, An Tai, Ergun Ahunbay, Elizabeth Gore, Candice Johnstone, X. Allen Li Medical College of Wisconsin NCC AAMP, Madison, Oct. 11, 2013 Motivation:

More information

8/2/2011. Elements of a Process Flow Trying use good planning to eliminate iterations. Thanks for contributions to this talk from

8/2/2011. Elements of a Process Flow Trying use good planning to eliminate iterations. Thanks for contributions to this talk from Head and Neck Treatment Planning Disclosure Grants from Varian Medical System Thanks for contributions to this talk from Robert Foote, M.D. From M.D. Anderson Yolanda Garces, M.D. Lei Dong, Ph.D. Shelley

More information

Pre-Employment Screening and Inprocessing of New Employees

Pre-Employment Screening and Inprocessing of New Employees POLICY: 6Hx28:3B-02 Responsible Executive: Vice President, Organizational Development and Human Resources Policy Contacts: Director, HR Policy and Compliance Programs Specific Authority: 1001.64, F.S.

More information

RADIATION LEVEL IN CHINA AND PROTECTION STANDARDS

RADIATION LEVEL IN CHINA AND PROTECTION STANDARDS RADIATION LEVEL IN CHINA AND PROTECTION STANDARDS PAN ZIQIANG CHINESE SOCIETY OF RADIATION PROTECTION The 5th asian regional conference on the evolution of the system of radiological protection Chiba,

More information

Proposed Panel Agenda October 2014 CPT Editorial Panel Meeting

Proposed Panel Agenda October 2014 CPT Editorial Panel Meeting Proposed Panel Agenda October 2014 CPT Editorial Panel Meeting The proposed agenda for the October 2014 CPT Editorial Panel meeting shows the code application names, code(s) affected, and a description

More information

MIIG INJECTABLE Graft The following languages are included in this packet:

MIIG INJECTABLE Graft The following languages are included in this packet: MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)

More information

SBRT LUNG CANCER CLINICAL PATHWAY

SBRT LUNG CANCER CLINICAL PATHWAY SBRT LUNG CANCER CLINICAL PATHWAY Final Draft March 2015 Cancer Clinical Performance Group Radiation Oncology SBRT Workgroup Membership: Rex Hoffman, MD, Clinical Lead, Disney Family Cancer Center (Burbank,

More information

Low Dose, Lightning Speed, Latest Applications

Low Dose, Lightning Speed, Latest Applications RXL EDITION Low Dose, Lightning Speed, Latest Applications The New Standard for Radiology Toshiba Medical Systems is committed to the development of new technologies to minimize radiation dose while maintaining

More information

DME REGIONAL Carrier. DME REGIONAL Carrier. service (not separately payable). If other. DME REGIONAL Carrier. DME REGIONAL Carrier

DME REGIONAL Carrier. DME REGIONAL Carrier. service (not separately payable). If other. DME REGIONAL Carrier. DME REGIONAL Carrier A0021 - A0999 Ambulance Services Local Carrier A4206 - A4209 Medical, Surgical, and Self- Local Carrier if incident to a physician s Administered Injection Supplies A4210 Needle Free Injection Device A4211

More information

Setting up Jack Figures for Motion Tracking

Setting up Jack Figures for Motion Tracking Setting up Jack Figures for Motion Tracking 1 Copyright Copyright Notice and Terms of Use Copyright (c) 2013 Siemens Product Lifecycle Management Software Inc. All rights reserved. This documentation is

More information

FLORIDA WORKERS COMPENSATION HEALTH CARE PROVIDER REIMBURSEMENT MANUAL Edition

FLORIDA WORKERS COMPENSATION HEALTH CARE PROVIDER REIMBURSEMENT MANUAL Edition FLORIDA WORKERS COMPENSATION HEALTH CARE PROVIDER REIMBURSEMENT MANUAL 2008 Edition Department of Financial Services Florida Department of Financial Services Division of Workers Compensation for incorporation

More information

N.MAFFEI, G.GUIDI, C.VECCHI, G.BALDAZZI Physics Department, University of Bologna, via Irnerio Bologna, Italy

N.MAFFEI, G.GUIDI, C.VECCHI, G.BALDAZZI Physics Department, University of Bologna, via Irnerio Bologna, Italy AN ARTIFICIAL NEURAL NETWORK TO PREDICT TIME OF REPLANNING FOR TOMOTHERAPY TREATMENTS N.MAFFEI, G.GUIDI, C.VECCHI, G.BALDAZZI Physics Department, University of Bologna, via Irnerio 40 40138 Bologna, Italy

More information

REDI MART TOBACCO Drug-Free Workplace Policy

REDI MART TOBACCO Drug-Free Workplace Policy REDI MART TOBACCO Drug-Free Workplace Policy Redi Mart Tobacco (referred to as The Company) is firmly committed to providing a drug-free workplace for the safety of its employees and for the safety of

More information

[Escambia County Board of County Commissioners]

[Escambia County Board of County Commissioners] [Escambia County Board of County Commissioners] Employee In-Processing SUBSTANCE ABUSE Title: Substance Abuse Policy Section II, Part C.12 Date Adopted: December 16, 1997 Effective Date: August 1, 2016,

More information

Billing with National Drug Codes (NDCs) Frequently Asked Questions

Billing with National Drug Codes (NDCs) Frequently Asked Questions Billing with National Drug Codes (NDCs) Frequently Asked Questions NDC Overview Converting HCPCS/CPT Units to NDC Units Submitting NDCs on Professional/Ancillary/Facility Claims Claims Reimbursement Details

More information

Functional Assessment and Clinical Outcome

Functional Assessment and Clinical Outcome Tissue Engineering Functional Assessment and Clinical Outcome STEVEN A. GOLDSTEIN Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan 48109,

More information

03/08/2017. Advances and Challenges in Contour QA for Adaptive RT. Objective. Disclosures

03/08/2017. Advances and Challenges in Contour QA for Adaptive RT. Objective. Disclosures Advances and Challenges in Contour QA for Adaptive RT Kristy K Brock, PhD, DABR, FAAPM Professor, Department of Imaging Physics Director, Image Guided Cancer Therapy Program University of Texas MD Anderson

More information

Mastering APCs: Optimizing Outpatient Revenues and Improving Compliance

Mastering APCs: Optimizing Outpatient Revenues and Improving Compliance Mastering APCs: Optimizing Outpatient Revenues and Improving Compliance James M. Georgoulakis Ph.D., MBA APC Advisory Group Deborah Sheets RN, CPHQ Plante & Moran, PLLC OBJECTIVES Provide info to enhance

More information

R/F. Experiences Using SONIALVISION safire and the Utility of Tomosynthesis. 1. Introduction. 2. Basics of Tomosynthesis.

R/F. Experiences Using SONIALVISION safire and the Utility of Tomosynthesis. 1. Introduction. 2. Basics of Tomosynthesis. R/F Experiences Using SONIALVISION safire and the Utility of Tomosynthesis Radiology Division, Dokkyo Medical University Koshigaya Hospital Masahiro Nakajima Mr. Masahiro Nakajima 1. Introduction The hospital

More information

Knowledge-based treatment planning: fundamentally different, or more of the same?

Knowledge-based treatment planning: fundamentally different, or more of the same? Knowledge-based treatment planning: fundamentally different, or more of the same? Kevin L. Moore, Ph.D., DABR Associate Director of Physics Manager of Dosimetry Group Disclosure Statement Patent for dosimetric

More information

Stereotactic Body Radiation Therapy: Planning and Delivery

Stereotactic Body Radiation Therapy: Planning and Delivery Stereotactic Body Radiation Therapy: Planning and Delivery Yong Yang, Ph.D. Department of Radiation Oncology Stanford University 6 AAPM Therapy Educational Course Stanford Radiation Physics Lei Xing, Ph.D.

More information

SEMINAR ON HEALTH CARE SYSTEMS INNOVATION. Comparative Effectiveness The Savior"? ESD.69 HST.926. October, 2012

SEMINAR ON HEALTH CARE SYSTEMS INNOVATION. Comparative Effectiveness The Savior? ESD.69 HST.926. October, 2012 SEMINAR ON HEALTH CARE ESD.69 HST.926 SYSTEMS INNOVATION Comparative Effectiveness The Savior"? Stan N. Finkelstein, M.D. Massachusetts Institute of Technology October, 2012 1 Patient Centered Outcomes

More information

Useful applications of radioactivity and nuclear energy Power for good... and evil

Useful applications of radioactivity and nuclear energy Power for good... and evil Useful applications of radioactivity and nuclear energy Power for good... and evil Nuclear power: environmental The greatest environmental threat is perceived to be global warming the build-up of greenhouse

More information

What is an Investigational Drug? 21CFR312.3(b)

What is an Investigational Drug? 21CFR312.3(b) Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany

More information

MND Review of Molecular and Genomic Diagnostic Testing Services Questions & Answers

MND Review of Molecular and Genomic Diagnostic Testing Services Questions & Answers MND Review of Molecular and Genomic Diagnostic Testing Services Questions & Answers 1. What is the Molecular and Genomic Testing Program? Horizon Blue Cross Blue Shield of New Jersey has expanded its collaboration

More information

Intensity Modulated Radiation Therapy: The good, the bad, and the misconceptions. Indications for IMRT. Indications for IMRT Billing

Intensity Modulated Radiation Therapy: The good, the bad, and the misconceptions. Indications for IMRT. Indications for IMRT Billing 1 Intensity Modulated Radiation Therapy: The good, the bad, and the misconceptions. J. M. Galvin, D.Sc. Department of Radiation Oncology Jefferson Medical College, Thomas Jefferson University Philadelphia,

More information

ICD-10 Trends Real Talk OBJECTIVES: Disclaimers FHIMA 6/8/2016. KYoumans 1. Karen Youmans, MPA, RHIA, CCS President, YES HIM Consulting, Inc.

ICD-10 Trends Real Talk OBJECTIVES: Disclaimers FHIMA 6/8/2016. KYoumans 1. Karen Youmans, MPA, RHIA, CCS President, YES HIM Consulting, Inc. ICD-10 Trends Real Talk Karen Youmans, MPA, RHIA, CCS President, YES HIM Consulting, Inc. OBJECTIVES: At the end of this session, the attendee will be able to: Discuss coder productivity under ICD-10-CM/PCS

More information

POSITION APPLYING FOR: Date of Application / /

POSITION APPLYING FOR: Date of Application / / Goodwill Industries-Knoxville, Inc. Application For Employment 5307 Kingston Pike, P.O. Box 11066 Knoxville, TN 37919 (865)588-8567 (865)588-0075 GWIK 4-02 Goodwill considers all applicants for employment

More information

2017 Media Kit INDUSTRY-LEADING HCP REACH POWERFUL MOBILE SOLUTIONS PROVEN ROI

2017 Media Kit INDUSTRY-LEADING HCP REACH POWERFUL MOBILE SOLUTIONS PROVEN ROI 2017 Media Kit INDUSTRY-LEADING HCP REACH POWERFUL MOBILE SOLUTIONS PROVEN ROI Our Briefings Every morning, we deliver to more than 997,000 physicians, dentists, and HCPs 900,000 of whom are U.S. based

More information

Going Clinical with the Accuray Radixact System. The Montefiore Experience

Going Clinical with the Accuray Radixact System. The Montefiore Experience Going Clinical with the Accuray Radixact System The Montefiore Experience Disclaimer The views expressed in the presentation are those of the presenters and do not necessarily reflect the views or policies

More information

Myeloma bone disease and bisphosphonates Myeloma Infoguide Series

Myeloma bone disease and bisphosphonates Myeloma Infoguide Series Myeloma bone disease and bisphosphonates Myeloma Infoguide Series Symptoms and complications This Infoguide has been made possible thanks to the generosity of Myeloma UK supporters. To find out how you

More information

ACTIVITY-BASED COSTING: A PRACTICAL MODEL FOR COST CALCULATION IN RADIOTHERAPY

ACTIVITY-BASED COSTING: A PRACTICAL MODEL FOR COST CALCULATION IN RADIOTHERAPY doi:10.1016/s0360-3016(03)00579-0 Int. J. Radiation Oncology Biol. Phys., Vol. 57, No. 2, pp. 522 535, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front

More information

ALLODERM SELECT ALLODERM SELECT RESTORE

ALLODERM SELECT ALLODERM SELECT RESTORE ALLODERM SELECT ALLODERM SELECT RESTORE Regenerative Tissue Matrix Instructions for Use Processed from donated human tissue by: LifeCell Corporation One Millennium Way Branchburg, NJ 08876-3876 DESCRIPTION

More information

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TM CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TABLE OF CONTENTS Section Port Styles 4 Description 5 Indications 5 Contraindications 5-6 Information

More information

SMARTBRUSH ANGIO. Version 1.0. Software User Guide Revision 1.0. Copyright 2014, Brainlab AG Germany. All rights reserved.

SMARTBRUSH ANGIO. Version 1.0. Software User Guide Revision 1.0. Copyright 2014, Brainlab AG Germany. All rights reserved. SMARTBRUSH ANGIO Version 1.0 Software User Guide Revision 1.0 Copyright 2014, Brainlab AG Germany. All rights reserved. TABLE OF CONTENTS TABLE OF CONTENTS GENERAL INFORMATION...5 Contact Data and Legal

More information

The SAVI TM Applicator: Breast Brachytherapy Training

The SAVI TM Applicator: Breast Brachytherapy Training The SAVI TM Applicator: Breast Brachytherapy Training SAVI Breast Brachytherapy Greater flexibility Treats the widest array of cavity & breast sizes Enhanced performance Eliminates skin spacing restrictions

More information

Billing I. Participant Workbook

Billing I. Participant Workbook Billing I Vision 5.2 (March 2015) Participant Workbook SourceMedical Learning Center of Excellence Last change made: March 2015 2015 Source Medical Solutions, Inc. All Rights Reserved. This document contains

More information

Shielding evaluation for IMRT implementation in an existing accelerator vault

Shielding evaluation for IMRT implementation in an existing accelerator vault JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 4, NUMBER 3, SUMMER 2003 Shielding evaluation for IMRT implementation in an existing accelerator vault R. A. Price,* O. Chibani, and C.-M. Ma Department

More information

Going back to Basic with Cost Accounting. Presented by Terrin Lands Director-Cost Reporting and RVU Development

Going back to Basic with Cost Accounting. Presented by Terrin Lands Director-Cost Reporting and RVU Development Going back to Basic with Cost Accounting Presented by Terrin Lands Director-Cost Reporting and RVU Development ASCENSION HEALTH FOOTPRINT Ascension is the largest Catholic health system, the largest private

More information

Ziehm Vision (FD) Vario 3D Exceptional 2D and 3D imaging with smallest footprint. > Flat-Panel Detector. > Image Intensifier

Ziehm Vision (FD) Vario 3D Exceptional 2D and 3D imaging with smallest footprint. > Flat-Panel Detector. > Image Intensifier Ziehm Vision (FD) Vario 3D Exceptional 2D and 3D imaging with smallest footprint > Flat-Panel Detector > Image Intensifier 02 03 Ziehm Vision Vario 3D Intraoperative 3D imaging with up to 512 3 voxel image

More information

The Effect of Medicare s New Technology Add-on Payment

The Effect of Medicare s New Technology Add-on Payment The Effect of Medicare s New Technology Add-on Payment A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Lindsay A. Bockstedt IN PARTIAL FULFILLMENT OF THE

More information

Motiva: a TV-based platform for remote patient management

Motiva: a TV-based platform for remote patient management Technology news New products Motiva: a TV-based platform for remote patient management a simplified user interface, a secure broadband connection and a standard set-top box. A nurse care manager, using

More information

Renal Dialysis Services

Renal Dialysis Services INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Renal Dialysis Services L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 4 5 P U B L I S H E D : N O V E M B E R 1 6, 2 0 1 7

More information

Types of Radiation Units

Types of Radiation Units RADIATION UNITS Types of Radiation Units Exposure in air - amount of ionization produced by or radiation in air. Unit - (R) or / (c/kg) Absorbed Dose energy transfer of / (unit of energy) of any. Used

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular

More information

3/6/2017 TOMOSYNTHESIS GUIDED BREAST BIOPSY LEARNING OBJECTIVES DISCLOSURES

3/6/2017 TOMOSYNTHESIS GUIDED BREAST BIOPSY LEARNING OBJECTIVES DISCLOSURES TOMOSYNTHESIS GUIDED BREAST BIOPSY Amy Kerger, D.O. Assistant Professor The Ohio State Wexner Medical Center Stefanie Spielman Comprehensive Breast Center LEARNING OBJECTIVES What is the difference between

More information

Laboratory Tests Chronic Renal Deficiency (CRD) Patients (NCD )

Laboratory Tests Chronic Renal Deficiency (CRD) Patients (NCD ) Policy Number 190.10 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 03/26/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare

More information

Implants for surgery Active implantable medical devices. Part 3: Implantable neurostimulators

Implants for surgery Active implantable medical devices. Part 3: Implantable neurostimulators Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 14708-3 Second edition 2017-04 Implants for surgery Active implantable medical devices Part 3: Implantable neurostimulators Implants chirurgicaux

More information